2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16297AS
    Abemaciclib-d8
    		Inhibitor 99.57%
    Abemaciclib-d8 is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
    Abemaciclib-d<sub>8</sub>
  • HY-148530
    YX-2-107
    		Degrader 99.79%
    YX-2-107 is a PROTAC (IC50= 4.4 nM) that selectively degrades CDK6. YX-2-107 effectively inhibits RB phosphorylation and FOXM1 expression in vitro and inhibits the development of Ph+ ALL in rats. YX-2-107 can be used in the study of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
    YX-2-107
  • HY-147007
    β-catenin-IN-3
    		Inhibitor
    β-catenin-IN-3 (Compound C2) is a selective β-catenin inhibitor. β-catenin-IN-3 binds to allosteric site on the surface of β-catenin with K D calculated at 54.96 nM. β-catenin-IN-3 selectively inhibits β-catenin via targeting a cryptic allosteric modulation site, lowers its cellular load. β-catenin-IN-3 significantly reduces viability of β-catenin driven cancer cells, and triggers β-catenin degradation via proteasome system in β-catenin-overexpressing cancer cells.
    β-catenin-IN-3
  • HY-117049
    Leucettine L41
    		Inhibitor 98.70%
    Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3 (IC50s = 0.04, 0.035, 0.015, and 4.5 µM, respectively). Leucettine L41 prevents lipid peroxidation and the accumulation of reactive oxygen species (ROS) induced by Aβ25-35 in the hippocampus in a mouse model of Alzheimer’s disease-like toxicity. Leucettine L41 also prevents memory deficits induced by Aβ25-35 in the same model.
    Leucettine L41
  • HY-117203A
    CDK12-IN-E9
    		Inhibitor 99.97%
    CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC50> 1 μM.
    CDK12-IN-E9
  • HY-114338A
    Dalpiciclib hydrochloride
    		Inhibitor 98.22%
    Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively. Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma.
    Dalpiciclib hydrochloride
  • HY-13231
    CDK9-IN-1
    		Inhibitor 98.52%
    CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC50 of 39 nM for CDK9/CycT1, extracted from reference, compound 87.
    CDK9-IN-1
  • HY-152219
    CLK1-IN-2
    		Inhibitor 98.73%
    CLK1-IN-2 is metabolically stable Clk1 inhibitor. CLK1-IN-2 has selectivity for Clk1 with an IC50 value of 1.7 nM. CLK1-IN-2 can be used for the research of tumour, Duchenne's muscular dystrophy and viral infections such as HIV-1 and influenza.
    CLK1-IN-2
  • HY-103221
    MeBIO
    		Inhibitor ≥98.0%
    MeBIO is a potent AhR (aryl hydrocarbon receptor) agonist, with IC50 of 44 μM (GSK-3) and 55 μM (CDK1/cyclin B), respectively.
    MeBIO
  • HY-50767S
    Palbociclib-d8
    		Inhibitor 99.84%
    Palbociclib-d8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].
    Palbociclib-d<sub>8</sub>
  • HY-15889
    AMG 925
    		Inhibitor 99.02%
    AMG 925 is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with IC50s of 2±1 nM and 3±1 nM, respectively.
    AMG 925
  • HY-111379
    EHT 5372
    		Inhibitor 98.12%
    EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC50s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively.
    EHT 5372
  • HY-15569
    NU6102
    		Inhibitor 99.23%
    NU6102 is a potent CDK1 and CDK2 inhibitor with IC50s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC50 of 1.6 μM), DYRK1A (IC50 of 0.9 μM), PDK1 (IC50 of 0.8 μM) and ROCKII (IC50 of 0.6 μM).
    NU6102
  • HY-P2559
    CDK7/9 tide
    		99.92%
    CDK7/9 tide is peptide substrate for CDK7 or CDK9.
    CDK7/9 tide
  • HY-148062
    RSS0680
    		98.03%
    RSS0680 (Example 22) is a bifunctional compound targeted protein degradation of kinases. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used for research of disease or disorder mediated by aberrant kinase activity.(Pink: FLT3-IN-17 (HY-148070); Black: Linker (HY-W041970); Blue: E3 ligase Ligand (HY-112078))
    RSS0680
  • HY-N6954
    Garcinone C
    		Inhibitor 99.66%
    Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active.
    Garcinone C
  • HY-16462
    CDK9-IN-2
    		Inhibitor 99.37%
    CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.
    CDK9-IN-2
  • HY-101257B
    YKL-5-124 TFA
    		Inhibitor 99.74%
    YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status.
    YKL-5-124 TFA
  • HY-103019B
    (-)-Enitociclib
    		Inhibitor 99.85%
    (-)-Enitociclib ((R)-Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC+ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies.
    (-)-Enitociclib
  • HY-145694
    CDK5-IN-3
    		Inhibitor 99.49%
    CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC50s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD).
    CDK5-IN-3
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

Pho85

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

CDK Degraders, Inhibitors, Antagonists & Activators
Product NameCDK1CDK2CDK3CDK4CDK5CDK6CDK7CDK8CDK9CDK11CDK12CDK13CDK14CDK16CDK19CDCCLKPho85Purity    
Palbociclib   
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
 
Cdk6/cyclin D2, IC50: 16 nM
            99.94%
Abemaciclib
CDK1/cyclinB1, IC50: 1627 nM
CDK2/cyclinE, IC50: 504 nM
 
Cdk4/cyclin D1, IC50: 2 nM
CDK5/p35, IC50: 287 nM
Cdk5/p25, IC50: 355 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
 
CDK9/cyclinT1, IC50: 57 nM
         99.97%
Ribociclib   
CDK4, IC50: 10 nM
 
CDK6, IC50: 39 nM
            99.94%
Ro-3306
CDK1, Ki: 20 nM
CDK1/cyclinB1, Ki: 35 nM
CDK1/cyclin A, Ki: 110 nM
CDK2/cyclinE, Ki: 340 nM
                99.83%
Dinaciclib
CDK1, IC50: 3 nM
CDK2, IC50: 1 nM
  
CDK5, IC50: 1 nM
   
CDK9, IC50: 4 nM
         99.64%
CPD-39   
CDK4
              
MU1210                
CLK1, IC50: 8 nM
CLK2, IC50: 20 nM
CLK4, IC50: 12 nM
 99.50%
CDK1-IN-6
CDK1
                 99.96%
Flavopiridol
CDK1/Cyc B1, IC50: 30 nM
CDK2/Cyc E, IC50: 170 nM
 
CDK4/Cyc D1, IC50: 100 nM
              99.73%
GSK3326595   
CDK4
 
CDK6
            99.83%
(R)-Roscovitine
cdc2/cyclin B, IC50: 0.65 μM
cdk2/cyclin A, IC50: 0.7 μM
Cdk2/cyclin E2, IC50: 0.7 μM
  
CDK5/p35, IC50: 0.16 μM
             99.53%
Palbociclib monohydrochloride   
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
 
Cdk6/cyclin D2, IC50: 16 nM
            99.98%
THZ1      
CDK7, IC50: 3.2 nM
           99.84%
Abemaciclib methanesulfonate
CDK1/cyclinB1, IC50: 1627 nM
CDK2/cyclinE, IC50: 504 nM
 
Cdk4/cyclin D1, IC50: 2 nM
Cdk5/p25, IC50: 355 nM
CDK5/p35, IC50: 287 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
 
CDK9/cyclinT1, IC50: 57 nM
         99.95%
AZD4573        
CDK9, IC50: 4 nM
         99.98%
Palbociclib isethionate   
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
 
Cdk6/cyclin D2, IC50: 16 nM
            99.99%
THZ531      
CDK7, IC50: 8.5 μM
 
CDK9, IC50: 10.5 μM
 
CDK12, IC50: 158 nM
CDK13, IC50: 69 nM
      99.86%
Kenpaullone
Cdk1/cyclin B, IC50: 0.4 μM
cdk2/cyclin A, IC50: 0.68 μM
CDK2/cyclinE, IC50: 7.5 μM
  
Cdk5/p25, IC50: 0.85 μM
             98.20%
Palbociclib hydrochloride   
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
 
Cdk6/cyclin D2, IC50: 16 nM
            99.89%
Wogonin       
CDK8
          99.92%
SR-4835          
CDK12, IC50: 99 nM
CDK12, Kd: 98 nM
CDK13, Kd: 4.9 nM
      99.73%
Toyocamycin 
CDK2/cyclinA, IC50: 0.67 μM
 
Cdk4/cyclin D3, IC50: 15 μM
 
cdk6/cyclin D3, IC50: >10 μM
CDK7/Mat1/cyclinH1, IC50: 2.8 μM
 
CDK9/cyclinT1, IC50: 79 nM
         99.78%
SNS-032
CDK1, IC50: 480 nM
CDK2, IC50: 38 nM
 
CDK4, IC50: 925 nM
  
CDK7, IC50: 62 nM
 
CDK9, IC50: 4 nM
         99.54%
SY-5609 
CDK2, Ki: 2600 nM
    
CDK7, Kd: 0.065 nM
 
CDK9, Ki: 960 nM
 
CDK12, Ki: 870 nM
       99.33%
GSK 3 Inhibitor IX
Cdk1/cyclin B, IC50: 320 nM
cdk2/cyclin A, IC50: 300 nM
 
Cdk4/cyclin D1, IC50: 10 μM
CDK5/p35, IC50: 80 nM
             99.73%
OTS964 hydrochloride         
CDK11B, Kd: 40 nM
        99.74%
Tagtociclib hydrate 
CDK2/cyclin E1, Ki: 1.16 nM
                99.95%
NVP-2        
CDK9, IC50: 0.5 nM
         99.60%
Amantadine 
CDK2
                99.90%
Samuraciclib hydrochloride
CDK1, IC50: 1.8 μM
CDK2, IC50: 578 nM
 
CDK4, IC50: 49 μM
CDK5, IC50: 9.4 μM
CDK6, IC50: 34 μM
CDK7, IC50: 41 nM
 
CDK9, IC50: 1.2 μM
         99.98%
Simurosertib               
Cdc7, IC50: <0.3 nM
  99.94%
JNJ-7706621
Cdk1/cyclin B, IC50: 9 nM
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
CDK3/Cyclin E, IC50: 58 nM
Cdk4/cyclin D1, IC50: 253 nM
 
CDK6/cyclinD1, IC50: 175 nM
            99.91%
hSMG-1 inhibitor 11j
CDK1, IC50: 32 μM
CDK2, IC50: 7.1 μM
                99.82%
AT7519
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
         99.76%
MBQ-167               
Cdc42, IC50: 78 nM
  99.64%
KB-0742 dihydrochloride        
CDK9/cyclinT1, IC50: 6 nM
         99.24%
CPS2 
CDK2, IC50: 24 nM
                99.33%
BI-1347       
CDK8, IC50: 1.1 nM
          99.84%
(+)-Enitociclib        
CDK9/CycT1, IC50: 3 nM
         99.89%
AZD-5438
cdk1-cyclin B1, IC50: 16 nM
cdk2-cyclin E, IC50: 6 nM
cdk2-cyclin A, IC50: 45 nM
 
cdk4-cyclin D1, IC50: 449 nM
cdk5-p25, IC50: 14 nM
cdk6-cyclin D3, IC50: 21 nM
cdk7-cyclin H, IC50: 821 nM
 
cdk9-cyclin T, IC50: 20 nM
         99.91%
TG003                
CLK1, IC50: 20 nM
CLK2, IC50: 200 nM
CLK4, IC50: 15 nM
 99.57%
Fadraciclib 
CDK2
      
CDK9
         99.78%
Ribociclib hydrochloride   
CDK4, IC50: 10 nM
 
CDK6, IC50: 39 nM
            99.95%
Flavopiridol Hydrochloride
CDK1/Cyc B1, IC50: 30 nM
CDK2/Cyc E, IC50: 170 nM
 
CDK4/Cyc D1, IC50: 100 nM
              99.73%
AS2863619       
CDK8, IC50: 0.61 nM
      
CDK19, IC50: 4.28 nM
   99.94%
BSJ-4-116          
CDK12, IC50: 6 nM
       98.73%
Ribociclib succinate   
CDK4, IC50: 10 nM
 
CDK6, IC50: 39 nM
            99.93%
CVT-313
Cdk1/cyclin B, IC50: 4.2 μM
cdk2/cyclin A, IC50: 0.5 μM
 
Cdk4/cyclin D1, IC50: 215 μM
              99.90%
(R)​-​CR8
Cdk1/cyclin B, IC50: 0.09 μM
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
  
Cdk5/p25, IC50: 0.11 μM
 
CDK7/cyclin H, IC50: 1.1 μM
 
CDK9/Cyclin T, IC50: 0.18 μM
         99.61%
YKL-5-124 
CDK2, IC50: 1300 nM
    
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
 
CDK9, IC50: 3020 nM
         98.79%
CLK-IN-T3                
CLK1, IC50: 0.67 nM
CLK2, IC50: 15 nM
CLK3, IC50: 110 nM
 98.63%
SLK/STK10-IN-1                
CLK2, IC50: 39 nM
 99.78%
BTX-A51      
CDK7, Kd: 1.3 nM
 
CDK9, Kd: 4 nM
         98.58%
TL12-186 
cdk2/cyclin A, IC50: 73 nM
      
CDK9/cyclinT1, IC50: 55 nM
         99.63%
hSMG-1 inhibitor 11e
CDK1, IC50: 32 μM
CDK2, IC50: 7.1 μM
                99.81%
NG 52
cdc2-cyclin B, IC50: 0.34 μM
   
Pho85p, IC50: 2 nM
             99.88%
Romaciclib monohydrochloride       
CDK8/CycC, IC50: 4.4 nM
CDK9/cycT, IC50: 1070 nM
     
CDK19/CycC, IC50: 10.4 nM
   99.29%
MSC2530818       
CDK8, IC50: 2.6 nM
          99.62%
Mevociclib      
CDK7
           99.27%
BSJ-03-204   
CDK4/D1, IC50: 26.9 nM
 
CDK6/D1, IC50: 10.4 nM
            99.76%
Nimbolide   
CDK4
 
CDK6
            99.79%
CGP60474
CDK1-Cyclin B, IC50: 26 nM
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
 
CDK4/cyclin D, IC50: 216 nM
Cdk5/p25, IC50: 10 nM
 
CDK7/cyclin H, IC50: 200 nM
 
CDK9/cycT, IC50: 13 nM
         98.90%
(E/Z)-Zotiraciclib 
CDK2, IC50: 13 nM
                99.96%
BSJ-04-132   
CDK4/D1, IC50: 50.6 nM
 
CDK6/D1, IC50: 30 nM
            99.07%
XL413 monohydrochloride               
Cdc7, IC50: 3.4 nM
  99.65%
PROTAC CDK2/9 Degrader-1 
CDK2, DC50: 62 nM
      
CDK9, DC50: 33 nM
         99.85%
BSJ-03-123     
CDK6
            98.12%
Ebvaciclib 
CDK2, Ki: 0.09 nM
 
CDK4, Ki: 0.13 nM
 
CDK6, Ki: 0.16 nM
            99.98%
CCT-251921       
CDK8, IC50: 2.3 nM
      
CDK19, IC50: 2.6 nM
   99.01%
Amantadine hydrochloride 
CDK2
                ≥98.0%
NU6300 
CDK2
                98.44%
FMF-04-159-2 
CDK2, IC50: 256 nM (in NanoBRET assay)
          
CDK14/Cyclin Y, IC50: 39.6 nM (in NanoBRET assay)
     99.48%
PF 477736
CDK1, Ki: 9.9 μM
                 99.21%
AUZ 454 
CDK2(C118L/A144C), Kd: 9.7 nM
CDK2(A144C), Kd: 15.4 nM
CDK2(C118L), Kd: 18.6 nM
CDK2(WT), Kd: 50 nM
CDK2(C118L/A144C-Cyclin B), Kd: 134.1 nM
                99.15%
XY028-140   
CDK4
 
CDK6
            98.52%
THZ1 Hydrochloride      
CDK7, IC50: 3.2 nM
           99.06%
CTX-712                
CLK2, IC50: 1.4 nM
 98.15%
Cucurbitacin E
cyclin B1/CDC2
                 99.92%
PHA-767491 hydrochloride
CDK1, IC50: 250 nM
CDK2, IC50: 240 nM
  
CDK5, IC50: 460 nM
   
CDK9, IC50: 34 nM
         99.49%
R547
Cdk1/cyclin B, Ki: 2 nM
Cdk1/cyclin B, IC50: 0.2 nM
CDK2/cyclinE, Ki: 3 nM
cdk2/cyclin A, IC50: 0.1 nM
CDK2/cyclinE, IC50: 0.4 nM
CDK3/Cyclin E, IC50: 0.8 nM
CDK4/cyclin D, Ki: 1 nM
CDK5/p35, IC50: 0.1 nM
cdk6/cyclin D3, IC50: 4 nM
CDK7/cyclin H, IC50: 171 nM
           99.57%
Roniciclib
Cdk1/cyclin B, IC50: 7 nM
CDK2/cyclinE, IC50: 9 nM
 
CDK4/cyclin D, IC50: 11 nM
  
CDK7/Cyclin H/MAT1, IC50: 25 nM
 
CDK9/cyclinT1, IC50: 5 nM
         98.09%
T025                
CLK1, Kd: 4.8 nM
CLK2, Kd: 0.096 nM
CLK3, Kd: 6.5 nM
CLK4, Kd: 0.61 nM
 99.64%
Purvalanol A
cdc2-cyclin B, IC50: 4 nM
cdk2-cyclin E, IC50: 35 nM
cdk2-cyclin A, IC50: 70 nM
 
cdk4-cyclin D1, IC50: 850 nM
cdk5-p35, IC50: 75 nM
             98.30%
BMS-265246
CDK1/cycB, IC50: 6 nM
CDK2/Cyc E, IC50: 9 nM
 
CDK4/cycD, IC50: 230 nM
              99.59%
Senexin A       
CDK8, Kd: 0.83 μM
CDK8, IC50: 280 nM
      
CDK19, Kd: 0.31 μM
   99.79%
LDC000067
cdk1-cyclin B1, IC50: 5513 nM
cdk2-cyclin A, IC50: 2441 nM
 
cdk4-cyclin D1, IC50: 9242 nM
    
CDK9- Cyclin T1, IC50: 44 nM
         99.00%
Senexin B       
CDK8, Kd: 140 nM
      
CDK19, Kd: 80 nM
   99.09%
BS-181 hydrochloride
CDK1/cycB, IC50: 8.1 μM
CDK2/Cyc E, IC50: 0.88 μM
 
CDK4/Cyc D1, IC50: 33 μM
CDK5/p35NCK, IC50: 3 μM
CDK6/cycD1, IC50: 47 μM
CDK7/CycH/MAT1, IC50: 0.021 μM
 
CDK9/cycT, IC50: 4.2 μM
         99.80%
Abemaciclib metabolite M2   
CDK4, IC50: 1.2 nM
 
CDK6, IC50: 1.3 nM
            99.94%
Asnuciclib
CDK1, IC50: 8.17 nM
CDK1, Ki: 4 nM
CDK2, IC50: 3.27 nM
CDK2, Ki: 3 nM
 
CDK4, IC50: 8.18 nM
 
CDK6, IC50: 37.68 nM
CDK7, IC50: 134.26 nM
CDK7, Ki: 91 nM
 
CDK9, IC50: 5.78 nM
CDK9, Ki: 4 nM
         99.76%
CDK2-IN-4
Cdk1/cyclin B, IC50: 86 μM
cdk2/cyclin A, IC50: 44 nM
                99.85%
THZ2
CDK1, IC50: 96.9 nM
CDK2, IC50: 222 nM
  
CDK5, IC50: 134 nM
 
CDK7, IC50: 13.9 nM
CDK8, IC50: 6830 nM
CDK9, IC50: 194 nM
         99.03%
SU9516
CDK1, IC50: 40 nM
CDK2, IC50: 22 nM
 
CDK4, IC50: 200 nM
              99.81%
Milciclib
cyclin B/CDK1, IC50: 398 nM
cyclin A/CDK2, IC50: 45 nM
cyclin E/CDK2, IC50: 363 nM
 
cyclin D1/CDK4, IC50: 160 nM
  
cyclin H/CDK7, IC50: 150 nM
           99.90%
PHA-793887
Cdk1/cyclin B, IC50: 60 nM
cdk2/cyclin A, IC50: 8 nM
CDK2/cyclinE, IC50: 8 nM
 
Cdk4/cyclin D1, IC50: 62 nM
Cdk5/p25, IC50: 5 nM
 
CDK7/cyclin H, IC50: 10 nM
 
CDK9/cyclinT1, IC50: 138 nM
         99.25%
(R)-CR8 trihydrochloride
CDK1/cyclinB1, IC50: 0.09 μM
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
  
Cdk5/p25, IC50: 0.11 μM
 
CDK7/cyclin H, IC50: 1.1 μM
 
CDK9/Cyclin T, IC50: 0.18 μM
         98.95%
Trilaciclib hydrochloride   
Cdk4/cyclin D1, IC50: 1 nM
 
cdk6/cyclin D3, IC50: 4 nM
            99.69%
JSH-150
Cdk1/cyclin B, IC50: 1.34 μM
cdk2/cyclin A, IC50: 2.86 μM
  
Cdk5/p25, IC50: 4.64 μM
 
CDK7/Cyclin H/MNAT1, IC50: 1.72 μM
 
CDK9/cyclinT1, IC50: 1 nM
   
CDK14/Cyclin Y, IC50: 1.68 μM
CDK16/Cyclin Y, IC50: 292 nM
    98.66%
CLK1-IN-1                
CLK1, IC50: 2 nM
 98.79%
Lerociclib dihydrochloride
CDK1/cyclinB1, IC50: 2.4 μM
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
 
Cdk4/cyclin D1, IC50: 1 nM
CDK5/p35, IC50: 832 nM
Cdk5/p25, IC50: 1.2 μM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
 
CDK9/Cyclin T, IC50: 28 nM
         98.11%
TC11
CDK1
                 99.55%
Atuveciclib
CDK1/CycB(h), IC50: 1100 nM
CDK2/CycE(h), IC50: 1000 nM
CDK3/CycE(h), IC50: 890 nM
 
CDK5/p35(h), IC50: 1600 nM
   
CDK9/CycT1, IC50: 13 nM
CDK9/CycT1(h), IC50: 6 nM
         99.80%
Narazaciclib   
Cdk4/cyclin D1, IC50: 3.9 nM
 
CDK6/cyclinD1, IC50: 9.82 nM
            99.12%
GFB-12811 
CDK2/CycA, IC50: 211 nM
  
Cdk5/p25, IC50: 2.3 nM
CDK6, IC50: 3197 nM
CDK7/Cyclin H/MAT1, IC50: 718 nM
 
CDK9/CycT1, IC50: 894 nM
         98.04%
CDK5 inhibitor 20-223 
CDK2, IC50: 6.0 nM
  
CDK5, IC50: 8.8 nM
             99.62%
XL413               
Cdc7, IC50: 3.4 nM
  99.76%
Abemaciclib metabolite M18 hydrochloride   
CDK4
 
CDK6
            98.18%
CDK12-IN-3          
CDK12, IC50: 491 nM
       99.86%
CP-10     
CDK6, DC50: 2.1 nM
            98.41%
LY2857785      
CDK7, IC50: 0.246 μM
CDK8, IC50: 0.016 μM
CDK9, IC50: 0.011 μM
         99.92%
MC180295
CDK1-Cyclin B, IC50: 138 nM
cdk2-cyclin A, IC50: 233 nM
cdk2-cyclin E, IC50: 367 nM
CDK3-Cyclin E, IC50: 399 nM
CDK4-Cyclin D, IC50: 112 nM
cdk5-p35, IC50: 159 nM
cdk5-p25, IC50: 186 nM
cdk6-cyclin D3, IC50: 712 nM
CDK7-CycH/MAT1, IC50: 555 nM
 
CDK9- Cyclin T1, IC50: 5 nM
         98.89%
PROTAC CDK9 Degrader-1        
CDK9
         98.03%
SEL120-34A hydrochloride       
CDK8/CycC, IC50: 4.4 nM
CDK9/cycT, IC50: 1070 nM
     
CDK19/CycC, IC50: 10.4 nM
   99.98%
Dalpiciclib   
CDK4, IC50: 12.4 nM
 
CDK6, IC50: 9.9 nM
            99.70%
Purvalanol B
cdc2/cyclin B, IC50: 6 nM
cdk2/cyclin A, IC50: 6 nM
CDK2/cyclinE, IC50: 9 nM
  
CDK5/p35, IC50: 6 nM
             
RGB-286638
cyclin B1-CDK1, IC50: 2 nM
cyclin E-CDK2, IC50: 3 nM
cyclin E-CDK3, IC50: 5 nM
cyclin D1-CDK4, IC50: 4 nM
p35-CDK5, IC50: 5 nM
cyclin D3-CDK6, IC50: 55 nM
cyclin H-CDK7, IC50: 44 nM
 
T1-CDK9, IC50: 1 nM
         99.70%
CDK12-IN-2 
CDK2, IC50: >100 μM
    
CDK7, IC50: >10 μM
CDK7, IC50: >10 μM
 
CDK9, IC50: 16 μM
 
CDK12, IC50: 52 nM
       99.36%
KH-CB19                
CLK1, IC50: 19.7 nM
CLK3, IC50: 530 nM
 99.31%
PROTAC CDK12/13 Degrader-1 TFA          
CDK12, DC50: 2.2 nM
CDK13, DC50: 2.1 nM
      99.12%
CKI-7 free base               
Cdc7
  99.80%
Alsterpaullone
Cdk1/cyclin B, IC50: 35 nM
cdk2/cyclin A, IC50: 15 nM
CDK2/Cyc E, IC50: 200 nM
  
CDK5/p35, IC50: 40 nM
             99.85%
ML167  
CDK3, IC50: ＞10000 nM
             
CLK4, IC50: 136 nM
CLK1, IC50: 1522 nM
CLK2, IC50: 1648 nM
 98.62%
Thiabendazole
CCNE1
CDK2
                99.77%
(±)-Enitociclib        
CDK9
         99.87%
FN-1501 
cdk2/cyclin A, IC50: 2.47 nM
 
Cdk4/cyclin D1, IC50: 0.85 nM
 
CDK6/cyclinD1, IC50: 1.96 nM
            99.08%
Voruciclib
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
  
CDK4/Cyc D1, Ki: 3.96 nM
 
CDK6/cycD1, Ki: 2.92 nM
  
CDK9/cyc T2, Ki: 0.626 nM
CDK9/CycT1, Ki: 1.68 nM
         99.77%
AZ5576        
CDK9, : <5 nM
         99.88%
Tambiciclib        
CDK9
         99.21%
Riviciclib hydrochloride
CDK1-Cyclin B, IC50: 0.079 μM
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.500 μM
 
cdk4-cyclin D1, IC50: 0.063 μM
 
cdk6-cyclin D3, IC50: 0.396 μM
  
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
         99.08%
CC-671                
CLK2, IC50: 0.006 μM
 99.06%
BRD6989       
CDK8, IC50: ~200 nM
recombinant CDK8, IC50: ~0.5 μM
      
recombinant CDK19, IC50: >30 μM
   99.56%
JH-XI-10-02       
CDK8, IC50: 159 nM
          99.82%
Bisindolylmaleimide X hydrochloride 
CDK2, IC50: 200 nM
                98.90%
XY028-133   
CDK4
 
CDK6
            98.62%
YX-2-107     
CDK6, IC50: 4.4 nM
            99.79%
β-catenin-IN-3   
Cdk4/cyclin D1
              
CDK12-IN-E9 
cdk2/cyclin A, IC50: 932 nM
    
CDK7/Cyclin H/MNAT1, IC50: 1210 nM
 
CDK9/cyclinT1, IC50: 23.9 nM
         99.97%
Dalpiciclib hydrochloride   
CDK4, IC50: 12.4 nM
 
CDK6, IC50: 9.9 nM
            98.22%
CDK9-IN-1        
CDK9/CycT1, IC50: 39 nM
         98.52%
MeBIO
Cdk1/cyclin B, IC50: 55 μM
   
Cdk5/p25, IC50: >100 μM
             ≥98.0%
Palbociclib-d8   
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
 
Cdk6/cyclin D2, IC50: 16 nM
            99.84%
AMG 925
CDK1, IC50: 1.9 μM
CDK2, IC50: 375 nM
 
CDK4, IC50: 3 nM
 
CDK6, IC50: 8 nM
            99.02%
EHT 5372                
CLK1, IC50: 22.8 nM
CLK2, IC50: 88.8 nM
CLK4, IC50: 59.0 nM
 98.12%
NU6102
Cdk1/cyclin B, IC50: 9.5 nM
CDK2/cyclin A3, IC50: 5.4 nM
 
CDK4, IC50: 1.6 μM
              99.23%
RSS0680
CDK1
CDK2
 
CDK4
 
CDK6
       
CDK16/Cyclin Y
    98.03%
Garcinone C      
CDK7
           99.66%
CDK9-IN-2        
CDK9, IC50: 5 nM (H929 multiple myeloma cell line)
         99.37%
YKL-5-124 TFA 
CDK2, IC50: 1300 nM
    
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
 
CDK9, IC50: 3020 nM
         99.74%
(-)-Enitociclib        
CDK9
         99.85%
CDK5-IN-3 
CDK2/CycA, IC50: 18 nM
  
Cdk5/p25, IC50: 0.6 nM
             99.49%
XO44
CDK1
CDK2
 
CDK4
              99.38%
Tabersonine   
CDK4
              98.14%
Flavone
CDK1/cyclinB1
                 99.85%
Abemaciclib metabolite M20   
CDK4
 
CDK6
            
LY3177833               
Cdc7, IC50: 3.3 nM
  99.48%
Ipivivint 
CDK2, EC50: 1 nM
CDK3, EC50: 7 nM
               99.95%
Samuraciclib hydrochloride dihydrate
CDK1, IC50: 1.8 μM
CDK2, IC50: 578 nM
 
CDK4, IC50: 49 μM
CDK5, IC50: 9.4 μM
CDK6, IC50: 31 μM
CDK7, IC50: 41 nM
 
CDK9, IC50: 1.2 μM
         99.08%
HS-243                
CLK4, IC50: 662 nM
 99.95%
LDC4297      
CDK7, IC50: 0.13 nM
           98.25%
Avotaciclib
CDK1
                 99.72%
NU6140
CDK1-Cyclin B, IC50: 6.6 μM
cdk2-cyclin A, IC50: 0.41 μM
 
CDK4-Cyclin D, IC50: 5.5 μM
cdk5-p25, IC50: 15 μM
 
cdk7-cyclin H, IC50: 3.9 μM
           99.07%
CDK9 inhibitor HH1        
CDK9
         99.69%
K00546
Cdk1/cyclin B, IC50: 0.6 nM
cdk2/cyclin A, IC50: 0.5 nM
              
CLK1, IC50: 8.9 nM
CLK3, IC50: 29.2 nM
 98.08%
JH-XVI-178       
CDK8, IC50: 1 nM
      
CDK19, IC50: 2 nM
   98.87%
Olomoucine 
cdk2-cyclin A, IC50: 7 μM
cdk2-cyclin E, IC50: 7 μM
  
cdk5-p35, IC50: 25 μM
             99.87%
CDK-IN-2        
CDK9/cyclinT1, IC50: 8 nM
         98.97%
CDK2-IN-3 
CDK2, IC50: 60 nM
                
DS96432529       
CDK8
          99.93%
BSJ-01-175          
CDK12
CDK13
      99.45%
GW8510 
CDK2
  
CDK5
             99.64%
FIT-039        
CDK9/cyclinT1, IC50: 5.8 μM
         99.56%
KB-0742        
CDK9/cyclinT1, IC50: 6 nM
         99.38%
Avotaciclib hydrochloride
CDK1
                 99.75%
Senexin C       
CDK8/CycC, IC50: 3.6 nM
CDK8/CycC, Kd: 1.4 nM
      
CDK19/CycC, Kd: 2.9 nM
   98.06%
CDK4/6-IN-15 
CDK2, IC50: 3.335 μM
 
CDK4, IC50: 3 nM
 
CDK6, IC50: 0.279 μM
            99.32%
DB0614     
CDK6
       
CDK16/Cyclin Y
    98.80%
CDK9-IN-7   
CDK4/cyclin D, IC50: 148 nM
 
CDK6/cyclinD, IC50: 145 nM
  
CDK9/cyclinT1, IC50: 11 nM
         98.05%
LL-K8-22       
CDK8, DC50: 2.52 μM
          99.76%
TP-1287        
CDK9
         
CDK4/6-IN-2   
CDK4, IC50: 2.7 nM
 
CDK6, IC50: 16 nM
            99.82%
GSK-3 inhibitor 3 
CDK2, IC50: 0.22 μM
  
CDK5, IC50: 1.3 μM
             98.72%
CDK8-IN-11       
CDK8, IC50: 46 nM
          98.20%
CDK8-IN-13       
CDK8, IC50: 51.9 nM
          99.14%
RGB-286638 free base
cyclin B1-CDK1, IC50: 2 nM
cyclin E-CDK2, IC50: 3 nM
cyclin E-CDK3, IC50: 5 nM
cyclin D1-CDK4, IC50: 4 nM
p35-CDK5, IC50: 5 nM
cyclin D3-CDK6, IC50: 55 nM
cyclin H-CDK7, IC50: 44 nM
 
T1-CDK9, IC50: 1 nM
         98.07%
Butyrolactone I
CDK1
                 98.03%
Atuveciclib Racemate        
CDK9
         98.48%
Avotaciclib trihydrochloride
CDK1
                 99.75%
CDK9-IN-13
CDK1, IC50: 0.14 μM
CDK2, IC50: 0.72 μM
    
CDK7, IC50: 0.40 μM
 
CDK9, IC50: <3 nM
 
CDK12, IC50: 0.055 μM
       99.94%
Cimpuciclib tosylate   
CDK4, IC50: 0.49 nM
 
CDK6, IC50: 9.56 nM
            99.16%
LDC4297 hydrochloride      
CDK7, IC50: 0.13 nM
           98.23%
NSC 625987   
CDK4/D1, IC50: 0.2 μM
              98.58%
AZD5597
CDK1, IC50: 2 nM
CDK2, IC50: 2 nM
                98.09%
CK7 
CDK2
      
CDK9
         99.72%
Manzamine A hydrochloride    
CDK5, IC50: 1.5 μM
             99.66%
DB1113   
CDK4
     
CDK11B
        99.28%
CLK1-IN-3                
CLK1, IC50: 5 nM
CLK2, IC50: 42 nM
CLK4, IC50: 108 nM
 98.03%
Casein Kinase inhibitor A86      
CDK7, Kd: 0.31 nM
 
CDK9, Kd: 5.4 nM
         99.26%
NU2058
CDK1, IC50: 26 μM
CDK2, IC50: 17 μM
CDK2, Ki: 12 μM
                99.66%
Longdaysin      
CDK7, IC50: 29 μM
           99.83%
AT7519 Hydrochloride
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
         99.42%
CDK9-IN-8        
CDK9, IC50: 12 nM
         99.65%
CDK1-IN-2
CDK1, IC50: 5.8 μM
                 
(E/Z)-Zotiraciclib hydrochloride 
CDK2
                99.90%
BGG463 
CDK2
                ≥98.0%
Desmethylglycitein
CDK1
CDK2
                98.98%
GW297361
yeast Cdk1, IC50: 20 nM
human CDK1, IC50: 30 nM
human CDK2, IC50: 1.9 nM
 
human CDK4, IC50: 300 nM
    
human CDK9, IC50: 10 nM
        
yeast Pho85, IC50: 400 nM
98.13%
NVP-LCQ195
Cdk1/cyclin B, IC50: 2 nM
cdk2/cyclin A, IC50: 2 nM
CDK2/cyclinE, IC50: 5 nM
CDK3/Cyclin E, IC50: 42 nM
 
Cdk5/p25, IC50: 1 nM
CDK5/p35, IC50: 1 nM
cdk6/cyclin D3, IC50: 187 nM
CDK7/Cyclin H/MAT1, IC50: 3564 nM
 
CDK9/cyclinT1, IC50: 15 nM
         98.81%
Ca2+ channel agonist 1 
CDK2, EC50: 3.34 μM
                99.71%
CA224 
cdk2-cyclin A, IC50: 521 μM
 
cdk4-cyclin D1, IC50: 6.2 μM
              99.94%
CAN508
Cdk1/cyclin B, IC50: 44 μM
CDK2/cyclinE, IC50: 20 μM
cdk2/cyclin A, IC50: 69 μM
 
Cdk4/cyclin D1, IC50: 13.5 μM
  
CDK7/cyclin H, IC50: 26 μM
 
CDK9/cyclinT1, IC50: 0.35 μM
         99.59%
AS2863619 free base       
CDK8, IC50: 0.61 nM
      
CDK19, IC50: 4.28 nM
   99.87%
BI-1622         
CDK11B
        98.97%
Samuraciclib hydrochloride hydrate
CDK1, IC50: 1.8 μM
CDK2/cycE1, IC50: 578 nM
 
CDK4, IC50: 49 μM
CDK5, IC50: 9.4 μM
CDK6, IC50: 34 μM
CDK7/CycH/MAT1, IC50: 41 nM
 
CDK9, IC50: 1.2 μM
         99.88%
(E/Z)-Zotiraciclib citrate 
CDK2
                98.06%
NU6027
CDK1, Ki: 2.5 μM
CDK2, Ki: 1.3 μM
                99.04%
CDK8/19-IN-1       
CDK8/CycC, IC50: 0.46 nM
CDK9, IC50: 270 nM
     
CDK19/CycC, IC50: 0.99 nM
   98.03%
CDK9-IN-11        
CDK9
         
PROTAC CDK12/13 Degrader-1          
CDK12, DC50: 2.2 nM
CDK13, DC50: 2.1 nM
      98.01%
NecroIr1   
CDK4
              98.02%
ABC1183        
CDK9- Cyclin T1, IC50: 321 nM
         99.19%
ON-013100   
Cdk4/cyclin D1
              99.66%
PHA-767491
CDK1, IC50: 250 nM
CDK2, IC50: 240 nM
  
CDK5, IC50: 460 nM
   
CDK9, IC50: 34 nM
         99.85%
Ribociclib succinate hydrate   
CDK4, IC50: 10 nM
 
CDK6, IC50: 39 nM
            99.96%
CDDD11-8        
CDK9, Ki: 8 nM
         99.62%
HTH-01-091      
CDK7, IC50: 1230 nM
           98.64%
CDK1-IN-1
CDK1/cycB, IC50: 161.2 nM
                 99.33%
HEMTAC CDK4/6 degrader 1   
CDK4
 
CDK6
            98.18%
Lacto-N-fucopentaose I 
CDK2/cyclinE
                99.92%
CDK12-IN-5 
CDK2/cyclinE, IC50: 173 μM
      
CDK9/cyclinT1, IC50: 127 μM
 
CDK12, IC50: 23.9 nM
       99.01%
THZ1-R      
CDK7, IC50: 146 nM
           98.12%
7BIO    
CDK5
             99.20%
CDK8-IN-1       
CDK8, IC50: 3 nM
          99.77%
YJ1206          
CDK12
CDK13
      
Voruciclib hydrochloride
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
  
CDK4/Cyc D1, Ki: 3.96 nM
 
CDK6/cycD1, Ki: 2.92 nM
  
CDK9/CycT1, Ki: 1.68 nM
CDK9/cyc T2, Ki: 0.626 nM
         99.23%
CDK7-IN-21      
CDK7
           
Cdk1/2 Inhibitor III
Cdk1/cyclin B, IC50: 2.1 μM
                 99.69%
Vanicoside B  
CDK3
               99.82%
Isosilybin B 
CDK2
 
CDK4
              99.32%
CDK2-IN-30 
CDK2, IC50: ≤ 20 nM
                
PNU112455A hydrochloride 
CDK2, Km: 3.6 μM
  
CDK5, Km: 3.2 μM
             99.56%
KH-CB20                
CLK1, IC50: 16.5 nM
CLK3, IC50: 488 nM
 99.80%
Ryuvidine   
CDK4, IC50: 6.0 μM
              99.40%
CDK9-IN-10        
CDK9
         98.09%
CDK9-IN-12        
CDK9/cyclinT1, IC50: 5.41 nM
         99.65%
(R)-DRF053 dihydrochloride
CDK1/cyclinB1, IC50: 220 nM
   
Cdk5/p25, IC50: 80 nM
             99.30%
(R)-(+)-O-Demethylbuchenavianine
CDK1, IC50: 1.1 μM
   
CDK5, IC50: 0.95 μM
             98.67%
PNU-292137
CDK1/cyclinB, IC50: 270 nM
CDK2/cyclinA, IC50: 37 nM
CDK2/cyclin E, IC50: 92 nM
 
CDK4/cyclinD1, IC50: >10000 nM
Cdk5/p25, IC50: 114 nM
             99.93%
Lerociclib
CDK1/cyclinB1, IC50: 2.4 μM
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
 
Cdk4/cyclin D1, IC50: 1 nM
CDK5/p35, IC50: 0.832 μM
Cdk5/p25, IC50: 1.2 μM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
 
CDK9/Cyclin T, IC50: 28 nM
         98.35%
NSC693868
Cdk1/cyclin B, IC50: 600 nM
   
Cdk5/p25, IC50: 400 nM
             ≥99.0%
YKL-1-116      
CDK7
           98.67%
RGB-286147
CDK1/cyclinB, IC50: 48 nM
CDK2/E, IC50: 15 nM
 
CDK4/D1, IC50: 839 nM
 
cdk6/cyclin D3, IC50: 232 nM
            98.60%
NecroIr2   
CDK4
              98.99%
CDK6/PIM1-IN-1
CDK1/cyclinB, IC50: >10 μM
CDK2/cyclinA, IC50: 2.274 μM
CDK3/Cyclin E, IC50: >10 μM
Cdk4/cyclin D1, IC50: 3.6 nM
Cdk5/p25, IC50: >10 μM
CDK6/cyclinD1, IC50: 39 nM
CDK7/Cyclin H/MNAT1, IC50: 393 nM
 
CDK9/cyclinT1, IC50: 440 nM
 
CDK12/Cyclin K, IC50: >10 μM
CDK13/Cyclin K, IC50: >10 μM
      
CLK1/2-IN-1                
CLK1, IC50: 16 nM
CLK2, IC50: 45 nM
 99.87%
BS-194
CDK1, IC50: 30 nM
CDK2, IC50: 3 nM
  
CDK5, IC50: 30 nM
 
CDK7, IC50: 250 nM
 
CDK9, IC50: 90 nM
         99.36%
CGP-82996
CDK1/cyclinB, IC50: >100 μM
CDK2/cyclinA, IC50: >50 μM
CDK2/cyclin E, IC50: >50 μM
 
Cdk4/cyclin D1, IC50: 1.5 μM
CDK4/cyclin D2, IC50: >50 μM
CDK5/p35, IC50: 25 μM
CDK6/cyclinD1, IC50: 5.6 μM
Cdk6/cyclin D2, IC50: >50 μM
            98.12%
5-Iodo-indirubin-3'-monoxime
Cdk1/cyclin B, IC50: 25 nM
   
Cdk5/p25, IC50: 20 nM
             99.50%
CDK7-IN-4      
CDK7
           98.87%
PROTAC CDK4/6 degrader 1   
CDK4, DC50: 10.5 nM
 
CDK6, DC50: 2.5 nM
            98.88%
BSJ-5-63      
CDK7
 
CDK9
 
CDK12
       99.97%
TMX-2039
CDK1, IC50: 2.6 nM
CDK2, IC50: 1.0 nM
 
CDK4, IC50: 52.1 nM
CDK5, IC50: 0.5 nM
CDK6, IC50: 35 nM
CDK7, IC50: 32.5 nM
 
CDK9, IC50: 25 nM
         99.42%
CDK9-IN-14        
CDK9, IC50: 6.92 nM
         99.91%
CDK7-IN-1      
CDK7, IC50: 100 nM
           98.91%
(S)-LY3177833 hydrate               
Cdc7
  
BS-181
CDK1/cycB, IC50: 8.1 μM
CDK2/Cyc E, IC50: 0.88 μM
 
CDK4/Cyc D1, IC50: 33 μM
CDK5/p35NCK, IC50: 3 μM
CDK6/cycD1, IC50: 47 μM
CDK7/CycH/MAT1, IC50: 0.021 μM
 
CDK9/cycT, IC50: 4.2 μM
         98.10%
IV-361 
CDK2, Ki: ≥1000 nM
    
CDK7, Ki: ≤50 nM
           99.60%
AT7519 TFA
Cdk1/cyclin B, IC50: 210 nM
cdk2/cyclin A, IC50: 47 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
         
LY3177833 monhydrate               
Cdc7, IC50: 3.3 nM
  99.76%
CDK2-IN-22 
CDK2, IC50: 64.42 nM
                98.64%
PROTAC CDK9 degrader-9        
CDK9
         99.25%
CDK8 ligand 1       
CDK8
          
CDK2 degrader 4 
CDK2
                
YJ9069          
CDK12
CDK13
      
PT-262 
CDK2
                99.21%
CDK2/4/6-IN-2 
CDK2
 
CDK4
 
CDK6
            
Bohemine 
CDK2/cyclinE, IC50: 4.6 μM
cdk2/cyclin A, IC50: 83 μM
      
CDK9/cyclinT1, IC50: 2.7 μM
         98.93%
PROTAC CDK9 degrader-2        
CDK9, IC50: 17 μM (MCF-7 cells)
         
(E/Z)-BIO-acetoxime
CDK1/cyclinB, IC50: 63 μM
CDK2/cyclinA, IC50: 4.3 μM
  
Cdk5/p25, IC50: 2.4 μM
             
CDK1/Cyc B-IN-1
CDK1-Cyclin B, IC50: 97 nM
                 98.47%
CDK2 degrader 3 
CDK2
                
CDK5-IN-1    
CDK5
             98.47%
CDK12-IN-6 
CDK2/cyclinE, IC50: >20 μM
      
CDK9/cyclinT1, IC50: >20 μM
 
CDK12, IC50: 1.19 μM
       98.09%
Akt1&PKA-IN-1 
CDK2, IC50: 9.8 μM
                
CDK8-IN-12       
CDK8, Ki: 14 nM
          99.74%
JSH-009 dimaleate
CDK1/cyclinB, IC50: 5410 nM
CDK2/cyclinA, IC50: 6850 nM
CDK3/cyclin E1, IC50: >10 (Pan)
 
Cdk5/p25, IC50: 6950 nM
 
CDK7/Cyclin H/MNAT1, IC50: 3700 nM
CDK8/cyclin C, IC50: >10 (Pan)
CDK9/cyclinT1, IC50: 0.928 nM
CDK11, IC50: >10 (Pan)
  
CDK14/Cyclin Y, IC50: 2710 nM
CDK16/Cyclin Y, IC50: 195 nM
    
AMG 925 (HCl)
CDK1, IC50: 1.9 μM
CDK2, IC50: 375 nM
 
CDK4, IC50: 3 nM
 
CDK6, IC50: 8 nM
            
GSK-3 inhibitor 4 
CDK2, IC50: 0.47 μM
  
CDK5, IC50: 0.68 μM
             98.77%
Akt1&PKA-IN-2 
CDK2a, IC50: 0.69 μM
                
Manzamine A    
CDK5, IC50: 1.5 μM
             98.2%
SEL120-34A       
CDK8/CycC, IC50: 4.4 nM
CDK9/cycT, IC50: 1070 nM
     
CDK19/CycC, IC50: 10.4 nM
   
CDK2 degrader 5 
CDK2
                99.17%
Abemaciclib metabolite M18   
CDK4
 
CDK6
            98.01%
Abemaciclib metabolite M20-d8   
CDK4
 
CDK6
            99.26%
CDD-2807                
CLK4, IC50: 85 nM
CLK2, IC50: 101 nM
CLK1, IC50: 116 nM
 99.52%
JA397            
CDK14/Cyclin Y, EC50: 27.1 nM
CDK16/Cyclin Y, EC50: 39.0 nM
    
Palbociclib dihydrochloride   
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
 
Cdk6/cyclin D2, IC50: 16 nM
            
Palbociclib orotate   
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
 
Cdk6/cyclin D2, IC50: 16 nM
            
Samuraciclib
CDK1, IC50: 1.8 μM
CDK2/cycE1, IC50: 578 nM
 
CDK4, IC50: 49 μM
CDK5, IC50: 9.4 μM
CDK6, IC50: 34 μM
CDK7/CycH/MAT1, IC50: 41 nM
 
CDK9, IC50: 1.2 μM
         
CDK1-IN-5
CDK1, IC50: 42.19 nM
CDK2, IC50: 188.71 nM
  
CDK5, IC50: 354.15 nM
             
Cimpuciclib   
CDK4, IC50: 0.49 nM
 
CDK6, IC50: 9.56 nM
            
CDK1-IN-3
CDK1, IC50: 36.8 nM
CDK2, IC50: 305.17 nM
  
CDK5, IC50: 369.37 nM
             
OTS964         
CDK11B, Kd: 40 nM
        
ZLMT-12 
CDK2, IC50: 0.011 μM
      
CDK9, IC50: 0.002 μM
         
CDK7-IN-2 hydrochloride hydrate      
CDK7
           
BS-181 dihydrochloride 
CDK2, IC50: 880 nM
  
CDK5, IC50: 3000 nM
 
CDK7, IC50: 21 nM
 
CDK9, IC50: 4200 nM
         
CDK4/6-IN-3
CDK1, Ki: 110 nM
  
CDK4, Ki: 0.3 nM
 
CDK6, Ki: 2.2 nM
            
FN-1501-propionic acid 
CDK2
      
CDK9
         
CDK9-IN-9 
CDK2, IC50: 155 nM
      
CDK9, IC50: 1.8 nM
         
CDK7-IN-11      
CDK7, IC50: 4.2 nM
           
HDAC1/2 and CDK2-IN-1 
CDK2, IC50: 0.80 nM
                
Riviciclib
CDK1-Cyclin B, IC50: 0.079 μM
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.540 μM
 
cdk4-cyclin D1, IC50: 0.063 μM
 
cdk6-cyclin D3, IC50: 0.396 μM
  
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
         
CDK6/9-IN-1     
CDK6, IC50: 40.5 nM
  
CDK9, IC50: 39.5 nM
         
Senexin A hydrochloride       
CDK8, IC50: 280 nM
CDK8, Kd: 0.83 μM
      
CDK19, Kd: 0.31 μM
   
Amantadine sulfate 
CDK2
                
CDK7-IN-30
CDK1, IC50: >10000.00 nM
CDK2, IC50: 734.55 nM
CDK3, IC50: 370.40 nM
CDK4, IC50: 644.80 nM
CDK5, IC50: 3678.50 nM
CDK6, IC50: 1345.50 nM
CDK7, IC50: 7.21 nM
 
CDK9, IC50: 704.3 nM
         
CDK2-IN-41 
CDK2
                
CDK7-IN-6      
CDK7, IC50: ≤100 nM
           
CDK2/4-IN-1 
CDK2
 
CDK4
              
CDK7-IN-16      
CDK7, IC50: 1~10 nM
           
CDK8-IN-6       
CDK8, Kd: 13 nM
          
Haspin-IN-2                
CLK1, IC50: 445 nM
 
CDK4/6-IN-18   
CDK4
 
CDK6
            
CDK4/9-IN-1   
CDK4, IC50: 23 nM
    
CDK9, IC50: 12 nM
         
(S)-LY3177833               
Cdc7
  
CDK4/6-IN-23     
CDK6, IC50: 11 nM
            
CKI-7               
Cdc7
  
CDK4/6-IN-12   
CDK4, IC50: 592.3 nM
 
CDK6, IC50: 3090 nM
            
CDK8-IN-17       
CDK8, IC50: 9 nM
          
CDK8/19-IN-3       
CDK8
      
CDK19
   
CDK2-IN-12 
CDK2, IC50: 11.6 μM
      
CDK9, IC50: >12.5 μM
         
CDK7-IN-10      
CDK7, IC50: ＜100 nM
           
HDAC1/CDK7-IN-1      
CDK7, IC50: 893 nM
           
P-gp/CDK2-IN-1 
CDK2
                
CDK4/6-IN-7   
CDK4, IC50: 1.58 nM
 
CDK6, IC50: 4.09 nM
            
Multi-kinase-IN-4 
CDK2, IC50: 2.09 μM
                
Cdc7-IN-15               
Cdc7
  
CDKI-83
CDK1/B, Ki: 72 nM
CDK2/E, Ki: 232 nM
 
CDK4/D, Ki: 290 nM
  
CDK7/H, Ki: 405 nM
 
CDK9/T1, Ki: 21 nM
         
Aloisine A
CDK1/cyclinB, IC50: 0.15 μM
CDK2/cyclinA, IC50: 0.12 μM
CDK2/cyclinE, IC50: 0.4 μM
  
CDK5/p35, IC50: 0.16 μM
             
CDK7-IN-32      
CDK7
           
CDK9-IN-28        
CDK9/cyclinT1
         
LZ9
CDK1
cyclin B1/CDC2
                 
CLK1/4-IN-1                
CLK1, IC50: 9.7 nM
CLK4, IC50: 6.6 nM
 
CP-07        
CDK9
         
Carbonic anhydrase inhibitor 14 
CDK2, IC50: 20.3 μM
                
CDK4/6-IN-21 maleate   
CDK4, IC50: 3.88 nM
 
CDK6, IC50: 3.31 nM
            
CDK4/6-IN-20   
CDK4, IC50: 1.9 nM
 
CDK6, IC50: 14.2 nM
            
Wogonin (Standard)       
CDK8
          
ALK-IN-29 
CDK2
                
CDK2/4/6-IN-1 
CDK2, IC50: 2.5 nM
 
CDK4, IC50: 23.7 nM
 
CDK6, IC50: 44.3 nM
            
PARP1/CDK12-IN-1          
CDK12, IC50: 285 nM
       
CDK5-IN-4 
CDK2, IC50: 6.24 ± 2.8 μM
  
CDK5, IC50: 9.8 ± 2.29 μM
   
CDK9, IC50: 1.76 ± 0.3 μM
         
CDK9-IN-24        
CDK9
         
TMX-3013
CDK1, IC50: 0.9 nM
CDK2, IC50: <0.5 nM
 
CDK4, IC50: 24.5 nM
CDK5, IC50: 0.5 nM
CDK6, IC50: 15.6 nM
            
XL413 hydrochloride               
Cdc7, IC50: 3.4 nM
  
SLM6        
CDK9/cyclinT1, IC50: 133 nM
         
CDK2-IN-8 
CDK2, IC50: 1.74 μM
                
CDK9-IN-33 
CDK2, IC50: 316.30 nM
 
CDK4, IC50: 1771.00 nM
 
CDK6, IC50: >10000 nM
CDK7, IC50: 160 nM
 
CDK9, IC50: 17.44 nM
         
CDK5-IN-2 
CDK2/CycA, IC50: 23 nM
  
Cdk5/p25, IC50: 0.2 nM
             
GSK3-IN-10   
CDK4, IC50: 3800 nM
            
CLK1, IC50: 620 nM
CLK4, IC50: 760 nM
CLK2, IC50: 800 nM
 
Cdc7-IN-14               
Cdc7, IC50: <1 nM
  
CDK2-IN-9 
CDK2, IC50: 0.63 μM
                
Cdc7-IN-13               
Cdc7, IC50: <1 nM
  
Fascaplysin   
CDK4
              
CDK9-IN-19        
CDK9/cyclinT1, IC50: 2 nM
         
CDK9-IN-22 
cdk2/cyclin A, IC50: 876.2 nM
      
CDK9/cyclinT1, IC50: 10.4 nM
         
NUAK1-IN-1   
CDK4
              
SHR5428
CDK1, IC50: >100 μM
CDK2, IC50: 8.99 μM
 
CDK4, IC50: 3.87 μM
 
CDK6, IC50: 5.89 μM
CDK7, IC50: 0.005 μM
 
CDK9, IC50: 8.30 μM
 
CDK12, IC50: 1.11 μM
       
CDK2-IN-20 
CDK2/cyclinE, IC50: 0.219 μM
                
CDK4/6-IN-14
CDK1, IC50: >10000 nM
CDK2, IC50: 1045 nM
 
CDK4, IC50: 10 nM
 
CDK6, IC50: 16 nM
CDK7, IC50: 2595 nM
 
CDK9, IC50: 2664 nM
         
CDK4/6/BRD4-IN-1   
CDK4, IC50: 85 nM
 
CDK6, IC50: 106 nM
            
AG-012986
Cdk1/cyclin B, Ki: 44 nM
cdk2/cyclin A, Ki: 94 nM
 
CDK4, Ki: 9.2 nM
CDK5/p35, IC50: 22 nM
   
CDK9/Cyclin T, IC50: 4 nM
         
ZDLD20   
CDK4/CycD3, IC50: 6.51  μM
              99.84%
BLINK11
CDK1/Cly Y, IC50: 39.34 nM
CDK2/ClyA2, IC50: 83.43 nM
  
CDK5/p35, IC50: 17.09 nM
Cdk5/p25, IC50: 14.69 nM
   
cdk9-cyclin T, IC50: 83.43 nM
         
IIIM-290 
CDK2/A, IC50: 90 nM
      
CDK9/T1, IC50: 94 nM
         
CDK4/6/HDAC-IN-1
CDK1, IC50: 55.6 nM
  
CDK4, IC50: 7.23 nM
 
CDK6, IC50: 13.2 nM
CDK6, IC50: 48.38 nM
            
CDK/HDAC-IN-2
CDK1, IC50: 8.63 nM
CDK2, IC50: 0.30 μM
 
CDK4, IC50: >1000 nM
 
CDK6, IC50: >1000 nM
CDK7, IC50: >1000 nM
           
CDK8-IN-10       
CDK8, IC50: 8.25 nM
          
ZLHQ-5f 
CDK2/CycA2, IC50: 0.145 μM
                
CDK4/6-IN-16   
CDK4, IC50: 13 nM
              
YY173   
CDK4, IC50: 7.7 nM
 
CDK6, IC50: 88 nM
            
KDM1/CDK1-IN-1
CDK1, IC50: 0.078 ± 2. μM
                 
CDK2-IN-43 
Cdk2/cyclin E2, IC50: 6 nM
                
CDK2-IN-36 
CDK2
                
CDK12/13-IN-2          
CDK12, IC50: 15.5 nM
CDK13, IC50: 12.2 nM
      
CDK2-IN-18 
CDK2/cyclinE, IC50: 8 nM
 
Cdk4/cyclin D1, IC50: 46 nM
              
CDK2/9-IN-1 
CDK2, IC50: 0.004 μM
      
CDK9, IC50: 0.009 μM
         
CDK7-IN-20
CDK1, IC50: 3375 nM
CDK2, IC50: 823 nM
CDK3, IC50: 1837 nM
 
CDK5, IC50: >10 (Pan)
CDK6, IC50: 950 nM
CDK7, IC50: 4 nM
 
CDK9, IC50: 526 nM
 
CDK12, IC50: >10 (Pan)
       
CDK9 autophagic degrader 1        
CDK9
         
CDK8-IN-7       
CDK8, Kd: 3.5 nM
          
CDK2-IN-7 
CDK2/cyclinE, IC50: 50 nM
                
CDK4/6-IN-21   
CDK4, IC50: 3.88 nM
 
CDK6, IC50: 3.31 nM
            
SHP2/CDK4-IN-1   
CDK4, IC50: 18.2 ± 1.3 nM
              
CDK8-IN-5       
CDK8, IC50: 72 nM
          
Anticancer agent 30 
CDK2
                
BMI-1026
CDK1, IC50: 2.3 nM
                 
CDK-IN-14 
CDK2/CycA2, IC50: 0.097 μM
                
JH-VIII-49       
CDK8, IC50: 16 nM
          
Cdc7-IN-18               
Cdc7, IC50: 1.29 nM
  
P162-0948       
CDK8, IC50: 50.4 nM
          
CDK2-IN-40 
CDK2/cyclinE, IC50: 10 nM
                
DDO-6079               
CDC37
  
CDK-TCIP1        
CDK9
         
Cdc7-IN-12               
Cdc7, IC50: <1 nM
  
EF-4-177 
CDK2/cyclinE, IC50: 87 nM
                
SZ-015268      
CDK7, IC50: 23.56 nM
           
PROTAC CDK9 degrader-6        
CDK942, DC50: 0.03 μM
CDK955, DC50: 0.05 μM
         
TMX-2172 
CDK2, IC50: 6.5 nM
  
CDK5, IC50: 6.8 nM
             
PROTAC CDK9/CycT1 Degrader-2        
CDK9, IC50: 45 nM
         
VCC972839:01        
CDK9, IC50: 7 nM
         
CLK1/2-IN-3                
CLK1, IC50: 1.1 nM
CLK2, IC50: 2.1 nM
 
FLT3/ITD-IN-4             
CDK16/Cyclin Y, EC50: 1768 nM
    
PSTAIR               
CDC28
  
CDK4 degrader 1   
CDK4
              
BLINK15
CDK1/Cly Y, IC50: 35.84 nM
CDK2/ClyA2, IC50: 44.12 nM
  
CDK5/p35, IC50: 29.34 nM
Cdk5/p25, IC50: 12.08 nM
   
CDK9/Cyclin T, IC50: 74.63 nM
         
CDK2-IN-29 
CDK2, IC50: 96 nM
 
CDK4, IC50: 360 nM
              
Autophagy agonist-1   
CDK4
              
3-Methylthienyl-carbonyl-JNJ-7706621
CDK1/cyclinB, IC50: 6.4 nM
CDK2/cyclinA, IC50: 2 nM
 
CDK4, IC50: 0.11 μM
              
CDK7-IN-8      
CDK7, IC50: 54.29 nM
           
CDK4/6-IN-9     
CDK6/cyclinD1, IC50: 905 nM
            
Cdc7-IN-19               
Cdc7, IC50: 1.49 nM
  
CDK2/PIM1-IN-1 
CDK2, IC50: 0.27 μM
                
ZLWT-37 
CDK2, IC50: 0.054 μM
      
CDK9, IC50: 0.002 μM
         
CDK2-IN-26 
CDK2
                
ZDLD13   
CDK4/CycD3, IC50: 0.38 μM
              
CDK1/2/4-IN-1
CDK1, IC50: 1.47
CDK2, IC50: 0.78
 
CDK4, IC50: 0.87
              
Antitumor agent-174
CDK1/cyclinB1
                 
CDK-IN-12   
CDK4, IC50: <20 nM
 
CDK6, IC50: <20 nM
            
CDK8-IN-18       
CDK8, IC50: 43 μM
          
Anticancer agent 29
CDK1/cyclinB1, IC50: 0.127 μM
CDK2/cyclinE, IC50: 0.054 μM
 
CDK4, IC50: 0.129 μM
 
CDK6, IC50: 0.396 μM
            
CDK7/9-IN-1      
CDK7, IC50: 5.74-65.6 nM
 
CDK9, IC50: 2.14 μM
         
CDK12-IN-7 
CDK2, IC50: 196 nM
        
CDK12, IC50: 42 nM
       
CDK12/13-IN-3          
CDK12, IC50: 107.4 nM
CDK13, IC50: 79.4 nM
      
CDK19 Probe 1              
CDK19, IC50: 1.01 μM
   
CDK12-IN-4 
CDK2/cyclinE, IC50: >20 μM
      
CDK9/cyclinT1, IC50: >20 μM
 
CDK12, IC50: 0.641 μM
       
Anticancer agent 264
CDK1/cyclinB1
CDK2/cyclinE
                
Ulecaciclib 
cdk2/cyclin A, Ki: 0.62 μM
 
Cdk4/cyclin D1, Ki: 0.2 nM
 
cdk6/cyclin D3, Ki: 3 nM
cdk7-cyclin H, Ki: 0.63 μM
           
CDK2-IN-28 
CDK2, Ki: 1 nM ([1])
  
CDK5, Ki: 15.8 nM ([1])
 
CDK7, Ki: 54.7 nM ([1])
 
CDK9, Ki: 12.8 nM ([1])
         
NUAK1-IN-2 
CDK2
 
CDK4
 
CDK6
            
CDK7-IN-28 
cdk2/cyclin A, IC50: 6224 nM
    
CDK7/Cyclin H/MNAT1, IC50: ＜5 nM
    
CDK13/Cyclin K, IC50: 152 nM
      
ZLC491          
CDK12
CDK13
      
PROTAC CDK9 degrader-8        
CDK9, IC50: 0.01 μM
         
CDK7-IN-31      
CDK7, Kd: 0.18 nM
           
PROTAC FLT3/CDKs degrader-1 
CDK2, DC50: 18.73 nM
                
CDK9-IN-32        
CDK9
         
CDK4/6-IN-8   
CDK4, IC50: 5.01 nM
 
CDK6, IC50: 3.97 nM
            
Indirubin-3'-monoxime-5-sulphonic acid
CDK1, IC50: 5 nM
   
CDK5, IC50: 7 nM
             
Multi-kinase-IN-6 
CDK2, IC50: 0.71 μM
                
CLZX-205        
CDK9, IC50: 2.9 nM
         
CDK9-IN-23        
CDK9, IC50: <20 nM
         
EGFR-IN-45 
CDK2, IC50: 1.6 μM
                
CDK-IN-9 
CDK2/E, IC50: 4 nM
  
Cdk5/p25, IC50: 39 nM
   
CDK9/T1, IC50: 20 nM
 
CDK12/K, IC50: 64 nM
CDK13/K, IC50: 22 nM
      
LDC3140      
CDK7, IC50: <5 nM
           
Aloisine RP106
Cdk1/cyclin B, IC50: 0.7 μM
   
Cdk5/p25, IC50: 1.5 μM
             
Indirubin-5-sulfonate
Cdk1/cyclin B, IC50: 55 nM
cdk2/cyclin A, IC50: 35 nM
CDK2/cyclinE, IC50: 150 nM
 
Cdk4/cyclin D1, IC50: 300 nM
CDK5/p35, IC50: 65 nM
             
PROTAC CDK9 degrader-5        
CDK942, DC50: 0.10 μM
CDK955, DC50: 0.14 μM
         
CDK2-IN-42          
CDK12
       
CDK4/6-IN-19   
CDK4, IC50: 0.2 nM
 
CDK6, IC50: 5.0 nM
            
CDK2-IN-31 
CDK2
                
CDK2-IN-15 
CDK2, IC50: 2.9 μM
                
Enitociclib        
CDK9
         
CDK7-IN-7      
CDK7, IC50: <50 nM
           
TMX-2138
CDK1/cyclinB, IC50: 8.7 nM
CDK2/cyclinA, IC50: 10.9 nM
 
CDK4/cyclinD1, IC50: 901 nM
Cdk5/p25, IC50: 7.0 nM
CDK6/cyclinD1, IC50: 465 nM
CDK7/cyclin H, IC50: 286 nM
 
CDK9/cyclinT1, IC50: 25.7 nM
         
CDK8-IN-15       
CDK8, IC50: 57 nM
          
YJZ5118          
CDK12
CDK13
      
LA-CB1   
CDK4
 
CDK6
            
CDK7-IN-5      
CDK7, IC50: <100 nM
           
CPD-10   
CDK4
              
Haspin-IN-1                
CLK1, IC50: 221 nM
 
CDK4/6-IN-10   
CDK4, IC50: 22 nM
 
CDK6/cyclinD1, IC50: 10 nM
            
CDK9-IN-36        
CDK9, IC50: 1.2 nM
         
CDK7-IN-29      
CDK7, IC50: 1.4 nM
           
CDK9/PARP-IN-1        
CDK9, IC50: 118 nM
         
CDK2-IN-44 
CDK2
                
ARN25499               
Cdc42
  
CDK2-IN-14-d3 
CDK2
                
CDK7-IN-27 
CDK2, IC50: 19.4 nM
    
CDK7, IC50: 3 nM
           
Avotaciclib sulfate
CDK1
                 
FLT3/CDK4-IN-1   
CDK4, IC50: 7 nM
              
Isosilybin B (Standard) 
CDK2
 
CDK4
              
CDK1-IN-4
CDK1, IC50: 44.52 nM
CDK2, IC50: 621.93 nM
  
CDK5, IC50: 135.22 nM
             
CDK2-IN-37 
CDK2
                
CDK8/19-IN-2       
CDK8/CycC, IC50: 2.08 nM
      
CDK19/CycC, IC50: 2.49 nM
   
JTK-101        
CDK9/cyclinT1
         
CDK2-IN-27
CDK1/cyclinB1, IC50: >10-20 nM nM
CDK2/cyclin E1, IC50: <10 nM
                
CDK9-IN-34        
CDK9, IC50: 0.25 μM
         
Tabersonine hydrochloride   
CDK4
              
2-Cyanoethylalsterpaullone
Cdk1/cyclin B, IC50: 0.23 nM
                 
CCT68127 
CDK2
    
CDK7
 
CDK9
         
Olomoucine II
Cdk1/cyclin B, IC50: 7.6 μM
CDK2/cyclinE, IC50: 0.1 μM
 
CDK4/cyclinD1, IC50: 19.8 μM
  
CDK7/cyclin H, IC50: 0.45 μM
 
CDK9/cycT, IC50: 0.06 μM
         
CDK8-IN-16       
CDK8, IC50: 5.1 nM
      
CDK19, IC50: 5.6 nM
   
(S)-Roscovitine
CDK1, IC50: ≤1 μM
CDK2, IC50: ≤1 μM
  
CDK5, IC50: ≤1 μM
 
CDK7, IC50: ≤1 μM
 
CDK9, IC50: ≤1 μM